Novo Nordisk acquires Dicerna for USD 3.3bn
Novo Nordisk is acquiring the US-based biotech business Dicerna for USD 3.3bn. The two companies are already collaborating within NASH, type 2 diabetes and obesity, in addition to rare diseases.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
On Thursday, Novo Nordisk announces in a press release that it is acquiring the US-based firm Dicerna, which has been a frequent collaborator of the Danish pharmaceutical company since 2019.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
